TY - JOUR
T1 - RAS testing of colorectal carcinoma-a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group.
AU - Wong, Newton Acs
AU - Gonzalez, David
AU - Salto-Tellez, Manuel
AU - Butler, Rachel
AU - Diaz-Cano, Salvador J
AU - Ilyas, Mohammad
AU - Newman, William
AU - Shaw, Emily
AU - Taniere, Philippe
AU - Walsh, Shaun V
PY - 2014/7/4
Y1 - 2014/7/4
N2 - Analysis of colorectal carcinoma (CRC) tissue for KRAS codon 12 or 13 mutations to guide use of anti-epidermal growth factor receptor (EGFR) therapy is now considered mandatory in the UK. The scope of this practice has been recently extended because of data indicating that NRAS mutations and additional KRAS mutations also predict for poor response to anti-EGFR therapy. The following document provides guidance on RAS (i.e., KRAS and NRAS) testing of CRC tissue in the setting of personalised medicine within the UK and particularly within the NHS. This guidance covers issues related to case selection, preanalytical aspects, analysis and interpretation of such RAS testing.
AB - Analysis of colorectal carcinoma (CRC) tissue for KRAS codon 12 or 13 mutations to guide use of anti-epidermal growth factor receptor (EGFR) therapy is now considered mandatory in the UK. The scope of this practice has been recently extended because of data indicating that NRAS mutations and additional KRAS mutations also predict for poor response to anti-EGFR therapy. The following document provides guidance on RAS (i.e., KRAS and NRAS) testing of CRC tissue in the setting of personalised medicine within the UK and particularly within the NHS. This guidance covers issues related to case selection, preanalytical aspects, analysis and interpretation of such RAS testing.
KW - COLORECTAL CANCER
KW - GENETICS
KW - LABORATORY MANAGEMENT
U2 - 10.1136/jclinpath-2014-202467
DO - 10.1136/jclinpath-2014-202467
M3 - Article
C2 - 24996433
SN - 1472-4146
JO - Journal Of Clinical Pathology
JF - Journal Of Clinical Pathology
ER -
